Andrew Cheng, President and CEO at Akero Therapeutics, Inc. (AKRO), sold 31,216 shares at $41.75 ($1.3M) on 2025-03-10, disclosed to the SEC on 2025-03-12.
Scheduled sale ($1.3M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $41.75 | 28,784 | $1.2M | 92.1% |
| 2 | $42.31 | 1,216 | $51K | 3.9% |
| 3 | $42.31 | 1,216 | $51K | 3.9% |
| Total | $41.79 avg | 31,216 | $1.3M | 100% |
| Filing → |
| AKRO | SELL | 2025-08-13 | $2.9M | — | Filing → |
| AKRO | SELL | 2025-07-11 | $3.1M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $726K | — | Filing → |